dry eye
Conditions
Interventions
Treatment group :bFGF gel Four times a day, every time a drop, 28 days
Control group:Substrate gel Four times a day, every time a drop, 28 days
Sponsors
Eye Institute of Xiamen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. participation in the clinical research, voluntary and sign a consent form; 2. gender unlimited, ages 18 to 75 years of age; 3. With clinical symptoms and signs of dry eye and clinical examination also conforms to: (1) One of the symptoms:dry sense, foreign body sensation, burning sensation, fatigue, discomfort, vision; (2) TBUT is less or equal than 10s but more than 0s,and Schirmer test I is from 2mm/5minutes to 5mm/5minutes; (3) Corneal fluorescein staining ? level:countable dot stain (without flake color fusion and filament); (4) Conjunctival fluorescein staining ? level:countable dot stain (without flake color fusion); 4. the study choice: patients' eyes are checked, for the signs and symptoms score high risk of eye eye; Such as integral equal, corneal fluorescein staining for the study of the heavier with eye, such as eyes fluorescein staining degree equal to take the right eye eye for research; 5. test in 3 months did not attend any other drug clinical trials; 6. don't use other medications, or use other drugs but has stopped for more than 2 weeks.
Exclusion criteria
Exclusion criteria: Every one of the following circumstances, not as the case: (1) the test allergy to any ingredient in the drug; (2) pregnant or lactating women or recently have fertility planners; (3) the clinical examination for fungi, bacteria, Angle, conjunctivitis in active patients; (4) with other conjunctiva, cornea and iris obvious pathological changes; (5) TBUT=0 s,or Schirmer Test<2mm/5minuts; (6) with serious heart, cerebrovascular, liver, kidney and hematopoietic system, severe primary disease; (7) nearly six months have eye surgery within or outside of the injured eye; (8) postmenopausal hormone replacement therapy; (9) lacrimal point embolism therapy nearly 1 month; (9) high intraocular pressure of patients with glaucoma or seen; (10) HSK infection history of patients; (11) may affect the outcome of treatment, such as systemic steroid hormones and immunosuppressive therapy); (12) experiments cannot stop wearing corneal contact lens; (13) patients with systemic or ocular long-term drug use may affect the research assessment; (14) during the test is no guarantee that drugs according to the requirements and with the visitor; (15) S'Sjoren syndrome, systemic disease and other ocular diseases that affect efficacy evaluation; (16) The researchers think there's any reason unsuitable for test in patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Conjunctival congestion degree;TBUT;Schirmer Test;Corneal staining scores;Conjunctival staining scores; | — |
Secondary
| Measure | Time frame |
|---|---|
| Goblet cell density;Cell karyoplasmic ratio;Squamous metaplasia; | — |
Countries
China
Contacts
Public ContactZuguo Liu
Outcome results
None listed